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Abstract: Background obesity and sedentary lifestyle have been shown to negatively affect survival 
in breast cancer (BC). The purpose of this study was to test the efficacy of a lifestyle intervention on 
body mass index (BMI) and physical activity (PA) levels among BC survivors in Modena, Italy, in 
order to show an outcome improvement in obese and overweight patients. Methods: This study is 
a single-arm experimental design, conducted between November 2009 and May 2016 on 430 women 
affected by BC. Weight, BMI, and PA were assessed at baseline, at 12 months, and at the end of the 
study. Survival curves were estimated among normal, overweight, and obese patients. Results: 
Mean BMI decreased from baseline to the end of the study was equal to 2.9% (p = 0.065) in 
overweight patients and 3.3% in obese patients (p = 0.048). Mean PA increase from baseline to the 
end of the study was equal to 125% (p < 0.001) in normal patients, 200% (p < 0.001) in overweight 
patients and 100% (p < 0.001) in obese patients. After 70 months of follow-up, the 5-year overall 
survival (OS) rate was 96%, 96%, and 93%, respectively in normal, obese, and overweight patients. 
Overweight patients had significantly worse OS than normal ones (HR = 3.69, 95%CI = 1.82–4.53 p = 
0.027) whereas no statistically significant differences were seen between obese and normal patients 
(HR 2.45, 95%CI = 0.68–8.78, p = 0.169). Conclusions: A lifestyle intervention can lead to clinically 
meaningful weight loss and increase PA in patients with BC. These results could contribute to 
improving the OS in obese patients compared to overweight ones. 
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1. Introduction 
Breast cancer (BC) is the most common cancer in women worldwide. In Italy, between 2008 and 
2012, breast cancer reached an age-standardized incidence rate of 126.9 per 100,000 women in 
northern Italy, 111.2 per 100,000 women in central Italy, and 98.9 per 100,000 women in southern 
Italy, Sicily, and Sardinia [1]. Since BC prognosis has significantly improved in developed countries 
due to earlier diagnosis and treatment improvements, BC survivors comprise the largest group of 
cancer survivors, with a prevalent number of cases equal to 799,196 in Italy. The five-year survival 
rate is equal to 87%; this rate is higher than both the European average (81.8%) and the North 
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European average (84.7%) [2]. However, BC outcome is different according to histological subtypes, 
defined by three broad biological subtypes, based on the expression of diagnostic biomarkers 
estrogen (ER) and progesterone (PR) receptor-positive; HER2 positive; and triple-negative (lacking 
hormone receptors and HER2). A further stratification of the disease includes six intrinsic subtypes 
(normal, claudin-low, luminals A and B, HER2 enriched and basal) [3] and four triple-negative 
molecular subtypes (basal-like 1, basal-like 2, mesenchymal and luminal androgen receptor) [4]. 
It is well known that obesity influences BC risk and affects survival in patients diagnosed with 
BC. For this reason, in a recent study, we evaluated the relationship between body mass index (BMI) 
and the risk of breast cancer (BC) as well as the outcome in 14,684 women recruited between ages 55 
and 69 who resulted eligible to participate in the mammography screening program (MSP) in the 
province of Modena, Italy. We reported a significantly higher risk of BC in obese women and we also 
demonstrated that obese women had more second events and poorer event-free survival compared 
to non-obese women [5]. 
Already in 2010, a review of 43 prospective studies evaluating the effect of obesity on BC 
prognosis had shown a poorer overall and BC-specific survival in obese patients compared to non-
obese women [6]. Two further meta-analyses have linked obesity and being overweight to a higher 
risk of recurrence and mortality [7,8]. A recent paper summarizes all studies on obesity and breast 
cancers showing an association with a 35% to 40% increased risk of breast cancer recurrence and 
death, thus resulting in poorer survival outcomes. This is most clearly established for estrogen 
receptor-positive breast cancer, with the relationship in triple-negative and human epidermal growth 
factor receptor 2–positive subtypes less well established. [9]. Also, weight gain after BC diagnosis has 
been associated with poorer prognosis [10]. 
On the other hand, physical activity (PA) has been associated with improved outcomes in BC 
survivors in many epidemiological studies [11–18], and meta-analysis confirmed that not only can 
PA reduce BC mortality, but it can also reduce several causes of mortality [19–22]. 
International recommendations for cancer prevention published in 2007 by the World Cancer 
Research Fund, include eating a healthy diet, being physically active and maintaining a healthy 
weight [23]. In the 2014 update report on BC survivors, the panel of experts concluded that evidence 
is still not strong enough to make specific recommendations for women with BC [24]. Nevertheless, 
there are indications of connections between better survival after BC and a healthy body weight, 
being physically active, eating foods containing high levels of fiber, eating foods containing soy, and 
including a lower intake of total fat in particular saturated fat in one’s diet [25]. 
Findings from experimental studies involving BC survivors suggest that a behavioral 
intervention may support clinically meaningful weight loss [26–30]. 
However, in our knowledge, no studies have reported the effects of lifestyle interventions on 
body weight in breast cancer survivors in the Italian population so far. 
The purpose of this single-arm pilot study was to test the feasibility and efficacy of a lifestyle 
intervention through diet and PA on body weight in a population of more than 400 patients with BC 
followed at Modena Cancer Center, Modena, Italy. 
2. Results 
A total of 430 patients were included in the study. Fifty-seven patients developed a second tumor 
(34 BCs and 23 other cancers). The time of study enrollment was equal to 78 months. Ninety-two 
patients left the study before the end (21.2%). On 31st March 2020, excluding seven patients who left 
the study during the first year, the median follow-up was equal to 70 months (range 12–124). The 
median follow-up was equal to 64 months in the underweight patients, 71 months in the normal 
weight group, 71 months in the overweight patients, and 70 months in the obese patients. The median 
time on treatment in underweight patients was 7 months, in normal weight patients was 84 months, 
in overweight patients was 64 months and in obese patients was 96 months. The median age at the 
diagnosis was 53 years (range 30–76 years). We observed that, considering BMI values, 3 (0.7%) 
patients were underweight at the baseline, 100 (23.3%) had normal weight, 167 (38.8%) were 
overweight, and 160 (37.2%) were obese. In total, 267 patients (76%) were overweight and obese. At 
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the last follow-up, 127 patients were undergoing hormonal treatment. Baseline characteristics of the 
study population are reported in Table 1. No differences were found in disease stage and type of 
therapies (chemotherapy alone, hormonal therapy alone, or combined treatments) among patient 
groups. When the only hormonal treatment was evaluated, aromatase inhibitors (AI) were the most 
frequently administered therapy, followed by tamoxifene, and lastly by a combination treatment. 
Normal weight patients received tamoxifene more frequently, whereas obese patients were mostly 
treated with AI (p = 0.041). On the whole, with regards to the menopausal status, the vast majority of 
patients were in postmenopausal condition (49.8%); this hormonal status was particularly 
predominant in obese women (56.9%) and overweight patients (52.1%), whilst 58% of normal weight 
patients were in premenopausal status (p < 0.001). Luminal cancers were the most frequent tumor 
subtype, being luminal A equal to 48.7% in the obese group and luminal B equal to 36.4% in the 
overweight group. Triple negative tumors arose more frequently in the normal weight group of 
patients (9%) (p = 0.001). A previous BC was particularly evidenced in overweight patients compared 
to other groups (p < 0.001). Finally, looking at tumor size and grade of invasive BC, obese patients 
showed the highest percentage of tumor larger than 5 cm (30%) (p = 0.001) and the highest percentage 
of grade III (60%) (p < 0.001) 
Table 1. Patients’ characteristics at baseline according to BMI groups. 
 All (n = 430) Underweight (n= 3) 
Normal  
(n = 100) 
Overweight 
 (n = 167) 
Obese  




Age (mean ± SD) 52.6 ± 23.4 56.7 ± 4.9 48.5 ± 9.3 53.1 ± 9.6 54.6 ± 10 0.032 
Stage at diagnosis 
N (%)      0.619 
In situ 18 (4.2) 0 3 (3.0) 5 (3.0) 10 (6.2)  
I 221 (51.4) 1 (33.3) 56 (56.0) 91 (54.5) 73 (45.6)  
II 128 (29.8) 1 (33.3) 24 (24.0) 49 (29.3) 54 (33.8)  
III 48 (11.1) 0 14 (14.0) 16 (9.6) 18 (11.3)  
IV 10 (2.3) 0 0 6 (3.6) 4 (2.5)  
nd 5 (1.2) 1 (33.4) 3 (3.0) 0 1 (0.6)  
Therapy N (%)      0.639 
CT only 29 (6.7) 0 7 (7.0) 11 (6.6) 11 (6.9)  
HT only 200 (46.5) 1 (33.3) 50 (50.0) 77 (46.1) 72 (45.0)  
CT+HT 181 (42.1) 1 (33.3) 39 (39.0) 74 (44.3) 67 (41.9)  
None 14 (3.5) 0 1 (1.0) 5 (3.0) 8 (5.0)  
nd 6 (1.6) 1 (33.4) 3 (3.0) 0 2 (1.2)  
Type of HT N (%)      0.041 
TAM 130 (34.2) 0 41 (46.6) 51 (34.0) 38 (27.1)  
AI 175 (45.9) 2 (66.7) 29 (33.0) 72 (48.0) 72 (51.4)  
TAM+AI 66 (17.3) 0 15 (17.0) 25 (16.7) 26 (18.6)  
nd 10 (2.6) 1 (33.3) 3 (3.4) 2 (1.3) 4 (2.9)  
Menopausal status 
N (%)      <0.001 
Premenopausal 182 (42.3) 0 58 (58.0) 71 (42.5) 53 (33.1)  
Post-menopausal 214 (49.8) 2 (66.7) 34 (34.0) 87 (52.1) 91 (56.9)  
nd 34 (7.9) 1 (33.3) 8 (8.0) 9 (5.4) 16 (10.0)  
Phenotype N (%)      0.001 
In situ 18 (4.2) 0 3 (3.0) 6 (3.6) 9 (5.6)  
Luminal A 189 (43.9) 0 48 (48.0) 63 (37.7) 78 (48.7)  
Luminal B 124 (28.9) 0 24 (24.0) 60 (35.9) 40 (25.0)  
Luminal/HER2 55 (12.8) 2 (66.7) 12 (12.0) 24 (14.4) 17 (10.6)  
HER2 enriched 11 (2.6) 0 2 (2.0) 5 (3.0) 4 (2.5)  
TNBC 29 (6.7) 0 9 (9.0) 9 (5.4) 11 (6.9)  
nd 4 (0.9) 1 (33.3) 2 (2.0) 0 1 (0.7) 
 
 
Second BC N (%) 34 (7.9) 0 8 (23.5) 17 (50.0) 9 (26.5) <0.001 
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Size invasive T  
N (%) 
     0.001 
≤2 cm 250 (60.9) 1 (33.3) 83 (85.6) 120 (74.1) 46 (30.7)  
>2 cm and ≤5 cm 90 (21.8) 0 11 (12.2) 36 (22.2) 43 (28.7)  
>5 cm 45 (10.9) 0 0 0 45 (30.0)  
nd 27 (6.4) 2 (66.7) 3 (2.2) 6 (3.7) 16 (10.6)  
Histology invasive 
BC N(%)      0.71 
Ductal 354 (85.9) 3 (100) 82 (84.5) 143 (88.3) 126 (84.0)  
Lobular 55 (13.4) 0 15 (15.5) 17 (10.5) 23 (15.3)  
nd 3 (0.7) 0 0 2 (1.2) 1 (0.7)  
Grade invasive BC 
N (%)      <0.001 
I 74 (18.0) 0 32 (33.0) 33 (20.4) 9 (6.0)  
II 156 (37.9) 1 (33.3) 34 (35.1) 69 (42.6) 52 (34.7)  
III 159 (38.5) 0 25 (24.7) 54 (33.3) 80 (60.0)  
nd 23 (5.6) 2 (66.7) 7 (7.2) 6 (3.7) 8 (5.3)  
Abbreviations: SD = standard deviation; Is = in situ carcinoma; nd = not determined; CT = 
chemotherapy; HT = hormonal therapy; TAM = tamoxifene; AI = aromatase inhibitors; TNBC = triple-
negative breast cancer; BC = breast cancer. * The ANOVA test was used to determine differences in 
clinicopathological features among groups. 
2.1. Weight, BMI, and Physical Activity 
In regard to the definitive results of the lifestyle intervention, only patients belonging to the 
overweight and obese groups derived a benefit. Any change in BMI was registered for underweight 
or normal-weight patients. As shown in Figure 1A, we reported a statistically significant BMI loss in 
the overweight patients from the beginning to the first year and in the obese group, from the 
beginning to the end of the study, whereas no statistically significant differences were seen in the 
underweight and normal-weight patients. Globally the median weight at the baseline was equal to 
74.1 (212 ± 20,6) kg and 70.4 (168 ± 18.3) kg at the last follow-up, with a statistically significant decrease 
of 5.5% (p < 0.001, mean difference −3.39, 95%CI = −4.41−2.36).). The differences in weight throughout 
the study period reflected the BMI changes amongst the four patients’ categories (Figure 1B). 
Particularly obese women had a weight reduction of 2.8 kg, moving from 86.8 to 84 kg (3.2%, p = 
0.048, mean difference −1.51, 95%CI = −1.80−0.01). Overweight women moved from 72.2 kg, at the 
entry to 67.6 after one year (−6.3% p < 0.001, mean difference −1.90, 95%CI = −3.10−0.70). In parallel, 
there were also highly significant (p < 0.001, mean difference 6.7, 95%CI =+ 5.6 + 7.8) changes in total 
physical activity levels. Normal patients increased their weekly activity by 1 h in the first year, from 
1.0 to 2.25 at the end of the study with an increment of 125% (p < 0.001, mean difference 1.83, 95%CI= 
+ 1.6 + 2.1), overweight patients increased physical activity moving from 0. to 2.0 h throughout the 
entire study period (increment of 200%) (p < 0.001, mean difference 95%CI= + 1.7+ 2.3) finally obese 
patients moved from 0 h per week to 1.0 throughout the study period (increment of 100%) (p < 
0.001,mean difference 1.47 95%CI = +1.1 + 1.8). 
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Figure 1. Figure 1 represents the BMI (A) and Kg (B) changes for patients categories’ throughout the 
study. (A) represents the body mass index (BMI) evaluation at the baseline (blue), at 12 months 
(orange) and at the end of the study (grey) in the underweight (UW), normal-weight (NW), 
overweight (OW) and obese patients by the whisker plot. The dots represent the outlier values. The 
estimated difference between BMI, weight, and physical activity along time-points was performed by 
means of ANOVA with repeated measures. No statistically significant differences (p = NS) were seen 
in the UW and NW groups along the time, whereas a statistically significant difference was shown in 
OW patients after one year from the baseline (p = 0.004, mean difference −0.72, 95%CI = −1.20−0.23), 
but not at the end of the study (p = 0.065, mean difference −0.45,95%CI = −1.1−0.54), and in obese 
patients (p = 0.048, mean difference −0.92, 95%CI = −1.82−0.01) at the end of the study, with a slow but 
progressive decrease of BMI. (B) represents weight evaluation at the baseline (blue), at 12 months 
(orange) and at the end of the study (gray) in the total population (all), underweight (UW), normal-
weight (NW), overweight (OW) and obese patients by the whisker plot. The dots represent the outlier 
values. Globally the median weight decreased from 74.1 to 70.4 kg at the end of the study (p < 0.001 
mean difference −3.39, 95%CI = −4.41−2.36), obese women moved from 86.8 to 84 kg (−3.2%, p = 0.04 
8, mean difference −1.51, 95%CI =−1.80 −0.01), overweight women moved from 72.2 kg, at the entry to 
67.6 after one year (−6.3% p < 0.001 mean difference −1.90, 95%CI = −3.10−0.70). No differences 
throughout the study period were seen for normal and underweight patients (p = NS). 
In Figure 2, differences in physical activity modification are shown for each group of patients. 
Either overweight or obese women show the most important changes in physical activity during the 
first year, with a slight decrease at the end of the study. 
In the overweight group the benefit of the intervention was more effective at 12 months, and less 
at the end of follow-up. In the obese group of patients there was a continuous benefit along the follow-
up period time. 
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Figure 2. The figure represents the physical activity as hours per week (h/w) evaluation at the baseline 
(blue), at 12 months (orange) and at the end of the study (gray) in underweight (UW), normal weight 
(NW), overweight (OW) and obese patients by the whisker plot. The dots represent the outlier values. 
The estimated difference in physical activity along time-points was performed by means of ANOVA 
with repeated measures. No statistically significant differences (p = NS) were seen in the UW group, 
whereas in the NW, OW, and obese groups, a statistically significant difference was shown (p < 0.001). 
2.2. Survival Curves 
Breast cancer recurrences including local and distant metastases occurred in 55 patients (12.8%). 
There were 38 (9.0%) patients who died from BC recurrences (24 patients) or other causes (14 
patients). Excluding patients with a follow-up less than 12 months and patients with a second tumor, 
the 5-year OS was equal to 95%, with 35 deaths, and the 5-year PFS corresponded to 90%, with 55 
relapses (Figure 3 A,B). In regard to the PFS, no statistically significant differences were seen among 
normal plus underweight patients versus overweight and obese patients (94 vs. 93 vs. 93 months, 
respectively) (Figure 4B). The association between overweight and obese women compared to normal 
and underweight women was not statistically significant (p = 0.097). 
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(A) (B) 
Figure 3. Five-year overall survival (OS), excluding patients with follow-up less than 12 months and 
with second tumors, was equal to 95% (A) and five-years progression free survival (PFS) was equal 
to 90% (B). 
Other causes of death were represented, in three cases by other cancers, in four cases by pneumonia 
disease whereas in the remaining seven cases the cause of death was unknown. No differences in BC 
specific survival were seen between overweight and normal patients (data not shown). Since only 3 
patients were underweight, they were combined with the normal weight patients; all together were 
compared to overweight and obese patients, having a statistically significant better OS (96 vs. 93 
months, p = 0.027, HR 3.69, 95%CI = 1.17−13.4)) than overweight patients, but not compared with obese 
patients (96 vs. 96 months, p = 0.169, HR 2.45, 95%CI = 0.68–8.78)) (Figure 4A). By associating 
overweight and obese patients, the OS comparison was equal to 96 months for underweight plus 
normal-weight patients and 94 months for overweight plus obese patients (p = 0.051, CI = 1.00–6.40). 
In regard to the PFS, no statistically significant differences were seen among normal plus underweight 
patients versus overweight and obese patients (94 vs. 93 vs. 93 months, respectively). (Figure 4B). The 
association between overweight and obese women compared to normal and underweight women 
was not statistically significant (p = 0.097). 
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Figure 4. The five-year overall survival (OS) and progression free survival (PFS), excluding patients 
with follow-up less than 12 months and with second tumors, was calculated in the three groups of 
patients; The OS in normal weight plus underweight patients (blue line) was 96% whereas in the 
overweight group (orange line) it was 93% (p = 0.027, HR 3.69, 95%CI = 1.17–13.4), and in the obese 
group (red line) it was 96% (p = 0.169, HR 2.45, 95%CI = 0.68–8.78) (A). The PFS was equal to 94% in 
the normal/underweight group (blue line), 93% in the overweight (orange line), and obese patients 
(red line). No statistically significant difference was seen amongst the groups (B). 
Table 2 describes survival analysis of weight and other characteristics by Cox’s proportional 
hazards regression for univariate analysis. No statistically significant differences were seen in OS and 
PFS for BMI, menopausal status, hormonal treatment, and tumor phenotype, although a worse 
prognosis was shown for overweight BMI, postmenopausal status, aromatase inhibitors treatment, 
and luminalB/luminal HER2 subtype. The only factor considered as statistically significant in 
univariate and multivariate analyses was a previous BC diagnosis (OS:HR = 2.78, p = 0.007; PFS:HR = 
3.10, p = 0.002). 
Table 2. Univariate analysis HR (95% CI) of OS and PFS. 
  OS   PFS  
Characteristics HR p value 95% CI HR p value 95% CI 
BMI       
Normal+UW 1.00 (ref.)   1.00 (ref.)   
Overweight 2.85 0.062 0.95–8.61 2.15 0.085 0.90–5.14 




Premenopausal 1.00 (ref.)   1.00 (ref.)   
Postmenopausal 1.58 0.399 0.55–4.56 0.94 0.885 0.41–2.16 
HT  
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TAM 1.00 (ref.)   1.00 (ref.)   
AI 1.44 0.487 0.52–3.99 1.16 0.749 0.47–2.88 
TAM+AI 0.83 0.771 0.23–2.97 0.55 0.328 0.17–1.82 
Phenotype  
Luminal A 1.00 (ref.)   1.00 (ref.)   
Luminal B 1.22 0.702 0.47–3.42 1.19 0.720 0.46–3.03 
Luminal/HER2 1.64 0.183 0.79–3.98 1.74 0.098 0.90–3.33 
HER2 enriched 0.88 0.934 0.20–3.7 0.60 0.624 0.32–2.4 
TNBC 1.35 0.326 0.72–2.99 1.21 0.124 0.88–3.5 
Previous BC 2.78 0.007 1.32–5.86 3.10 0.002 1.54–6.25 
Tumor size       
T≤2 cm 1.00 (ref.)   1.00 (ref.)   
T> 2 cm 2.08 0.026 1.09–3.95 1.73 0.079 0.94–3.21 
Stage       
0-I 1.00 (ref.)   1.00 (ref.)   
II 0.41 0.417 0.05–3.52 1.46 0.251 0.76–2.81 
III-IV 6.29 0.002 2.00–19.8 3.15 0.001 1.60–6.22 
Grading       
I 1.00 (ref.)   1.00 (ref.)   
II-III 1.78 0.258 0.81–4.33 1.82 0.074 0.96–4.55 
Abbreviations: HR = hazard ratio; CI = confidence interval; OS = overall survival; PFS = progression-
free survival; BMI = body mass index; UW = underweight; Ref. = reference; HT = hormonal therapy; 
TAM = Tamoxifene; AI = aromatase inhibitors; HER2 = human epidermal growth factor receptor 2; 
TNBC = triple-negative breast cancer; BC = breast cancer; T = tumor size. The Cox regression model 
was used to calculate hazard ratios 
A multivariate analysis among BMI, stage, and second tumors were performed in order to 
evidence if some factors were independently related to the overall survival in specific subgroups of 
patients (Table 3). Overweight patients, but not obese ones, BC diagnosed at stages III and IV, the 
presence of second tumors, and tumor size > 2 cm were independent risk factors of death 
Table 3. Multivariate Analysis HR (95% CI) of OS. 
  OS  
Characteristics HR p value 95% CI 
BMI    
Normal and UW 1.00 (ref.)   
Overweight 4.57 0.005 1.57–13.4 
Obese 2.77 0.072 0.91–8.39 
Stage    
I 1.00 (ref.)   
II 1.25 0.583 0.57–2.74 
III–IV 4.94 <0.001 2.46–9.92 
Second Tumor    
No 1.00 (ref.)   
Yes 4.49 <0.001 1.98–10.2 
T ≤ 2 cm 1.00 (ref.)   
T > 2 cm 2.04 0.031  1.07–3.88 
Abbreviations: HR = hazard ratio; CI = confidence interval; OS = overall survival; BMI = body mass 
index; Ref = reference; UW = underweight. T = tumor size. The Cox regression model was used to 
calculate hazard ratios. 
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The percentage of second tumor in normal plus underweight, overweight and obese patients 
was 2%, 5%, and 6% (p = 0.431). 
3. Discussion 
Weight is becoming a major health issue in the USA with > 60% of American adults being obese 
and overweight [31]. An association between risk of occurrence and obesity has previously been 
reported for various cancers. Recently, numerous studies including multivariate analyses 
demonstrated an independent prognosis effect of obesity on the risk of BC recurrence, PFS, and OS 
[5,6,32]. For example, a retrospective analysis of the Danish Breast Cancer Cooperative Group 
(DBCG) database including 18,967 BC patients, treated between 1977 and 2006, revealed that 
overweight or obese patients more often presented at diagnosis with features associated to poor 
prognosis. Even after adjusting for classical prognostic factors, obesity remained an independent risk 
factor for the development of disease metastases and for BC related death [33]. Similarly, a 
retrospective multivariate analysis of 2887 node-positive BC patients enrolled in the BIG 02-98 trials 
showed that obesity remained an independent prognostic factor for both PFS and OS despite more 
aggressive tumor characteristics in obese patients compared to non-obese counterparts at diagnosis [34]. 
The results of our study show that the rate of obese and overweight BC women was very high 
in Italian population (76%), despite following the Mediterranean diet [35]. Therefore, we investigated 
the feasibility and efficacy of a lifestyle intervention through diet and PA on body weight and 
therefore prognosis of 430 patients with BC followed at Modena Cancer Center, Modena, Italy. No 
differences in disease stage were found according to BMI, although obese patients showed the highest 
percentage of tumors larger than 5 cm and grade III, as well as demonstrated by several studies in 
which obese women develop significantly larger sizes or advanced BC compared to normal weight 
women [36], Our multivariable analysis confirms that being overweight patients is an independent 
risk factor of death, such as having an advanced stage at diagnosis (stage III and IV),and a tumor size 
larger than 2 cm, regardless of the weight. However, the increased number of second tumors in 
different BMI categories do not seem to have an impact on BC survival. 
The relationship between obese patients and AI treatment is well known, but we have clearly 
shown that obesity is a metabolic condition regardless the hormonal treatment and it is not the 
consequence of the therapy. In fact, obesity represents the most frequent condition in 
postmenopausal status, where AI are mostly used. However, as reported by a recent study that 
investigated the BC prognosis in obese women treated with AI [37], no worse outcome was seen 
compared to normal patients, not supporting the speculation that an elevated aromatase activity 
decreases the clinical efficacy of AIs in these women [38–42]. Our BC specific survival curves did not 
show a difference between overweight and normal patients, suggesting that other causes of death 
could impact on the worst prognosis in this group of women. In fact, the other causes of death were 
affecting the pulmonary district; it was particularly evident both in the obese group of patients (one 
died of acute respiratory distress syndrome, one of chronic obstructive pulmonary disease) and in 
the overweight group (the death was due to pneumonia disease in two cases). These disease 
conditions have been related to in increased body weight and a recent study has shown that a regular 
physical activity in overweight and obese patients is associated to a lower risk of developing those 
morbidities [43] 
We have shown a relationship between obese patients and luminal A subtype tumor, as already 
seen in another study [44]. The first objective of our research was reached and we demonstrated that, 
after ten years from the beginning of the study, healthy lifestyle guidelines provided by a dietician 
who lays out a personal program of nutrition education and PA is able to significantly reduce BMI 
and increase weekly PA in overweight and obese women. Moreover, obese women continue to 
decrease their weight and BMI after medical monitoring. 
Furthermore, we documented a statistically significant worse prognosis of overweight patients 
compared to obese and normal-weight patients. By the univariate analysis, no statistically significant 
differences were seen among BMI, menopausal status, or tumor phenotypes and survival curves, 
although a trend toward worse prognosis was revealed in overweight patients. Since the study was 
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concluded after seven years, we can’t derive any conclusion on the better prognosis of obese patients 
than overweight patients at the end of data collection. However, a longer intervention control and 
data registration could provide new insight on efficacy of this program. We are conscious that a 
benefit on other diseases, such as cardiovascular risk factors, or diabetes is probably seen with a BMI 
decrease in the range of 5–10%, being considered as secondary objective in a large randomized trial 
for adults with a recent diagnosis of type 2 diabetes [45], but it remains unclear whether a BMI 
decrease less than 5% can impact on BC prognosis 
The strength of this research derives from the methodology used to provide a real and effective 
lifestyle intervention in BC patients, able to statistically reduce body weight, particularly in 
overweight and obese women throughout the study period. A better prognosis in obese than in 
overweight women was seen, in contrast to the vast majority of studies where obesity represented 
the worst category of patients in terms of death and recurrence [46]. 
The limit is represented by the short period of follow-up, knowing that recurrences and death 
in patients with hormonal positivity tumors arise after the first five years from the diagnosis. This 
could have reduced the real impact of the lifestyle intervention on obese women, who show a 
significant yet slight decrease in weight and BMI. Probably an extension of the study would continue 
to improve health conditions of our patients. 
Another important limitation is the high drop-out rate from the study, particularly in the first 
year of intervention; a high rate in drop-out could probably be reduced by more frequent reminders 
to patients who do not obtain a BMI decrease at the first six month visit 
4. Materials and Methods 
4.1. Methods 
The study was approved by the Ethic Committee of Modena, Italy. It is a single-arm 
experimental design conducted to test the efficacy of a lifestyle intervention in patients with BC 
treated at Modena Cancer Center from November 2009 to May 2016. All participants provided 
written informed consent in accordance with the Declaration of Helsinki. 
4.2. Eligibility Criteria 
The study population included 430 women. We included patients with a new diagnosis of 
hormone positive breast cancer, treated by surgery, with or without radiotherapy, hormonal therapy, 
and/or chemotherapy in adjuvant setting. 
4.3. Study Procedures 
At the first visit, women were weighed and height was measured; arm, waist, and hip 
circumferences, along with the tricipital, bicipital, subscapular, and suprailiac folds were also 
measured; BMI, defined as weight in kilograms divided by height in meters squared (kg/m2). Based 
on the BMI, women were grouped into the weight categories recommended by the World Health 
Organization (WHO) [46]: underweight (BMI < 18.5 kg/m2), normal-weight (BMI = 18.5–24.9 kg/m2), 
overweight (BMI = 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2). Nutritional history and physical 
activity (hours/week) were inquired. Finally, the dietician provided patients with recommendations 
for a healthy lifestyle and a survey on their health status. 
One month later, following the evaluation of the survey on health status, the dietician provided 
patients with a personalized program of nutrition education and physical activity. Written resources 
containing the food pyramid, healthy eating guidelines and tips, basic information on portion size, 
examples to reduce food intake (maximum calorie reduction, 500 kcal/d), and dietary 
recommendations were delivered to patients. These latter were specifically designed and tailored 
taking into account nutritional needs, comorbidities, and other information and/or needs 
communicated during the first meeting and consisted of daily and weekly meal plans and 
suggestions for meal composition stimulating patients to self-arrange their diet according to the 
MedDiet. Patients were re-evaluated at 6, 12 months, and at the end of follow-up. During the 
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subsequent meetings, the dietician also evaluated the adherence to the dietary recommendations, 
made eventual adjustments, assessed anthropometry, and assisted participants in maintaining 
motivations. 
4.4. Definition of BC Subtypes 
Her2/neu testing was carried out at a single pathology laboratory in Modena by 
immunohistochemistry, and the results were scored as follows: 0, 1 = negative, 2 = indeterminate, and 
3 = positive. Patients with HER2 test results reported as “indeterminate” were evaluated by 
fluorescence in situ hybridization (FISH). ER and PgR testing were conducted with a single report 
format of “positive” or “negative” test results, as measured by immunohistochemical analysis (clone 
6F11, Ventana, for ER; and clone 1E2, Ventana, for PgR) and staining by Ventana Benchmark 
autostainer. ER and PgR receptor status were tested by evaluating the percentage of nuclear 
immunoreactivity with respect to all the nuclei in the neoplastic cells, independently of the staining 
intensity. Nuclear staining 10% of either ER or PgR was considered a positive result. Ki-67 labeling 
index was determined with the MIB1 monoclonal antibody as nuclear immunoreactivity. The cut-off 
was equal to 14% to subdivide luminal A and luminal B tumor. Luminal A were tumors with 
ER/PgR/HER2-/Ki67 < 14%, luminal B were tumors with ER/PgR/HER2-/Ki67 ≥ 14%, luminal/HER2 
enriched were tumors with ER/PgR/HER2, triple-negative tumors were ER-/PgR-/HER2-, and HER2 
were tumors with ER-/PgR-/HER2. 
4.5. Dietary Intervention 
The dietary intervention was based on the MedDiet which was first introduced and described 
by Keys et al. in “The Seven Countries Study”. Consequently, several other studies confirmed the 
beneficial effects and outcomes of the MedDiet on health mainly reducing mortality, cardiovascular 
disease risk factors, and cancer [47]. 
The MedDiet is based on a balanced use of foods rich in fiber, antioxidants, and unsaturated fats, 
a healthy approach designed to reduce the consumption of animal fats and cholesterol in a diet with 
an appropriate balance between energy intake and expenditure [35]. Therefore, the MedDiet is 
characterized by high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, 
moderate consumption of fish and poultry and low consumption of full-fat dairies, red meat and 
derived products, as well as homemade baked goods. Olive oil is the basic source of fat used for food 
preparation and condiment. Meals are often accompanied by low-to-moderate amounts of wine. The 
relationships between the macronutrient in the MedDiet is 55–60% of carbohydrates of which 80% 
complex carbohydrates (bread, pasta, rice), 10–15% of proteins about 60% of animal origin (especially 
white meat, fish), 25–30% fat (mostly olive oil) [35]. 
The MedDiet is typically represented graphically in the shape of a pyramid whose most updated 
version is described by Bach-Faig et al. [48]. The graphic representation follows the previous pattern: 
at the base, food items that should sustain the diet and provide the highest energy intake, and at the 
upper levels, foods to be eaten in moderate amounts such as animal source foods and foods which 
are high in sugars and fats that should be eaten in moderation or occasionally [48]. 
Along with recommendations regarding the proportion and frequency of food consumption, the 
incorporation of cultural and lifestyle elements is one of the innovations of the latest version of the 
pyramid. These concepts are represented outside of the pyramid, and at its base the following 
concepts are represented: moderation, socialization, culinary activities, physical activity, adequate 
rest, seasonality and tradition, local/homegrown products, eco-friendly and biodiverse products. 
Eating habits were recorded using a food diary. A food diary dietary assessment approach 
records consumption of food and beverages as they are consumed throughout the reporting day thus 
making it more accurate than food frequency questionnaires which depend on retrospective recall. 
We recommended a period of 7 days for record-keeping in the week leading up to follow up 
appointment. For checks after 3, 6, and 12 months, food diaries were recorded over a period of 7 days 
every month. Food diaries allow the patient to record all food intake in the established period, after 
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which the nutrient intake may be calculated and averaged. At the follow-up visits, we were able to 
address the compliance to the diet by food diary registration 
4.6. Physical Activity Program 
As far as physical activity is concerned, the counseling approach was mainly used to stimulate 
patients to increase their physical activity. A motivational method instead of a more common 
prescriptive method was used to favor a more active lifestyle taking an incremental approach i.e., 
trying to increase the general level of activity throughout the day and every day up to a sustainable 
and compatible level with physical conditions and available time. A physical activity diary, 
containing the type and duration of exercises, was offered in order to register the patient’s perception 
and comments every time. The aim was to maintain a regular activity over time or to provide an 
instrument for modifying some exercises in order to become more pleasant. A self-esteem evaluation 
was also registered and measured to reach a high level. 
During the meetings, patients and a dietician tried to set achievable goals tailored to the physical 
conditions of every single patient. People with (very) limited physical activity levels were stimulated 
to start identifying and ensuring ways to increase their physical activity. For example, obese patients 
were stimulated to identify daily activities that could increase their physical activity (e.g., walking, 
riding a bike, getting off the bus one stop before, walking up the stairs instead of taking the elevator, 
walking the dog, walking with their children, etc.). All patients without any physical constrain were 
stimulated to identify and take up/maintain regular physical activity. For these latter patients, the 
final goal was a habitual physical activity workload > 20 METs/h (where 1 MET is equal to 3.5 mL of 
oxygen spent for kg of weight per hour) in a week (corresponding to 3-h/wk moderate-intense 
physical activity) which was used in the study of Montesi et al. [49]. 
At the follow-up visits, patients exhibited the physical activity diary; the daily type and duration 
of exercises were registered in order to verify the compliance to the personal program. 
Patients who continued in the established program were satisfied with the results, in terms of 
behavioral changes. Many of them tried to convince all family members to change their lifestyle, 
according to the dietary intervention and physical activity program. On the contrary, patients who 
did not experience a change in weight and their BMI felt inadequate. 
4.7. Statistical Analysis 
A database was set up at our institution, which consisted of collecting individual details, weight, 
height, BMI, physical activity, and follow-up data, using the Excel program by Window version 10. 
The follow-up was calculated from the date of the BC onset to the endpoint of interest: the date of 
death or the end of the study period. The ANOVA test was used to determine differences in 
clinicopathological features between groups. Since the BMI, Kg, and PA were measured at different 
time points over the same patient, we checked the association of those variables as function of time 
points by means of ANOVA for repeated measure. We reported a raw p-value, not adjusted by 
multiple comparison. All statistical tests were two-sided. p < 0.05 was considered statistically 
significant, and the p-value was two-sided for all analyses. Survival curves were estimated using the 
Kaplan-Meier method including the log-rank test group comparison. Univariate and multivariate 
analyses of PFS and OS were conducted using a proportional hazards Cox regression model. All 
analyses were performed using the Stata statistical package (version 10 SE). 
5. Conclusions 
A lifestyle intervention can lead to clinically meaningful weight loss and increase PA in patients 
with BC. Our obese patients showed a better OS than overweight patients. The worst prognosis of 
overweight/obese patients aged over 55 years is likely related to death from other causes. 
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